To include your compound in the COVID-19 Resource Center, submit it here.

Motif's iclaprim meets in second Phase III for ABSSSIs

Motif Bio plc (LSE:MTFB; NASDAQ:MTFB) reported top-line data showing that iclaprim (MTF-100) met the primary endpoint of non-inferiority to vancomycin in the Phase III REVIVE-2 trial to treat acute bacterial skin and skin structure infections (ABSSSIs). The company plans to submit an

Read the full 426 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE